Regenxbio
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $21,359 | $89,012 | $21,214 | $24,197 |
Gross Profit | 12,245 | 85,576 | 14,896 | 11,810 |
EBITDA | -55,973 | 18,608 | -37,746 | -54,816 |
EBIT | -59,878 | 14,653 | -41,769 | -58,777 |
Net Income | -70,871 | 6,083 | -51,186 | -59,597 |
Net Change In Cash | 21,359 | 89,012 | 21,214 | 24,197 |
Free Cash Flow | -49,733 | 32,605 | -32,703 | -40,875 |
Cash | 79,558 | 130,104 | 57,526 | 56,617 |
Basic Shares | 51,483 | 51,434 | 50,871 | 50,800 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $83,328 | $90,242 | $112,724 | $470,347 |
Gross Profit | 49,761 | 53,029 | 58,179 | 418,514 |
EBITDA | -198,228 | -239,464 | -244,242 | 169,544 |
EBIT | -214,443 | -256,784 | -257,151 | 159,980 |
Net Income | -227,102 | -263,494 | -280,321 | 127,840 |
Net Change In Cash | 83,328 | 90,242 | 112,724 | 470,347 |
Cost of Revenue | 7,483 | |||
Free Cash Flow | -175,561 | -228,367 | -238,212 | 134,700 |
Cash | 57,526 | 34,522 | 96,952 | 345,209 |
Basic Shares | 49,509 | 43,734 | 43,152 | 43,913 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$1.38 |
2025-03-31 | $0.12 |
2024-12-31 | -$1.01 |
